C Annicchiarico
About
In The Last Decade
C Annicchiarico
20 papers receiving 348 citations
Peers
Comparison fields: 5 of 54
- Molecular Biology 136
- Reproductive Medicine 119
- Oncology 115
- Immunology 105
- Cancer Research 48
Countries citing papers authored by C Annicchiarico
This map shows the geographic impact of C Annicchiarico's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C Annicchiarico with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C Annicchiarico more than expected).
Fields of papers citing papers by C Annicchiarico
This network shows the impact of papers produced by C Annicchiarico. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C Annicchiarico. The network helps show where C Annicchiarico may publish in the future.
Co-authorship network of co-authors of C Annicchiarico
This figure shows the co-authorship network connecting the top 25 collaborators of C Annicchiarico. A scholar is included among the top collaborators of C Annicchiarico based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C Annicchiarico. C Annicchiarico is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 32 | |
| 2 | 39 | |
| 3 | Serum preoperative vascular endothelial growth factor (VEGF) in epithelial ovarian cancer: relationship with prognostic variables and clinical outcome. | 59 |
| 4 | Preoperative serum E-cadherin assay in patients with ovarian carcinoma. | 20 |
| 5 | Serum anti-p53 antibodies in the follow-up of patients with advanced ovarian carcinoma. | 17 |
| 6 | Serum assay of soluble CD44 standard (sCD44-st), CD44 splice variant v5 (sCD44-v5), and CD44 splice variant v6 (sCD44-v6) in patients with epithelial ovarian cancer. | 14 |
| 7 | 17 | |
| 8 | The serum assay of soluble CD44 standard (sCD44-st), CD44 splice variant 5 (sCD44-v5), and CD44 splice variant 6 (sCD44-v6) in patients with cervical cancer. | 3 |
| 9 | Preoperative serum antibodies against the p53 protein in patients with ovarian and endometrial cancer. | 25 |
| 10 | Preoperative serum intercellular adhesion molecule-1 (ICAM-1) and E-selectin (endothelial cell leukocyte adhesion molecule, ELAM-1) in patients with epithelial ovarian cancer. | 6 |
| 11 | Serum levels of soluble receptors for tumor necrosis factor (p55 and p75 sTNFr) in endometrial cancer. | 8 |
| 12 | 43 | |
| 13 | 17 | |
| 14 | Serum interleukin-6 levels in uterine malignancies. Preliminary data. | 14 |
| 15 | Serum CYFRA 21-1 assay in squamous cell carcinoma of the cervix. | 20 |
| 16 | Determination of serum levels of different cytokeratins in patients with uterine malignancies. | 7 |
| 17 | Serum measur¬ments of CA125, CA19.9, CA15.3, and TAG-72 in patients with epithelial ovarian cancer. | 1 |
| 18 | 6 | |
| 19 | Serum soluble interleukin-2 receptor (sIL-2R) assay in cervical and endometrial cancer. Preliminary data. | 6 |
| 20 | Pelvic ultrasound, serum CA125 assay, CA19.9 assay and serum CA72.4 assay in the differential diagnosis of ovarian masses | 3 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.